Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|February 18, 2014
A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)Haruyasu Murakami, Nobuyuki Yamamoto, Taro Shibata, et al.
International Journal of Clinical Oncology|May 17, 2024
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET studyKaname Nosaki, Kiyotaka Yoh, Ryo Toyozawa, et al.
Translational Lung Cancer Research|July 18, 2020
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323Toshiyuki Kozuki, Naoyuki Nogami, Osamu Hataji, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2015
A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)Yoshihiro Hattori, Miyako Satouchi, Temiko Shimada, et al.
Lung Cancer (Amsterdam, Netherlands)|October 31, 2016
Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective studyKaname Nosaki, Miyako Satouchi, Takayasu Kurata, et al.
Cancer Science|January 9, 2019
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancerMakoto Nishio, Toshiaki Takahashi, Hiroshige Yoshioka, et al.
Cancer Management and Research|December 22, 2021
Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)Motoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, et al.
The Lancet. Respiratory Medicine|November 10, 2016
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trialKiyotaka Yoh, Takashi Seto, Miyako Satouchi, et al.
The Lancet. Oncology|June 6, 2020
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trialJun Sato, Miyako Satouchi, Shoichi Itoh, et al.
JAMA Oncology|September 7, 2023
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled TrialMotoko Tachihara, Kayoko Tsujino, Takeaki Ishihara, et al.
Pageof 13